Beyond Alzheimer’s: Why Brain Health Research Can’t Stay in Silos
by
Alzheimer’s disease has long been studied as a distinct condition with its own symptoms, progression, and treatment strategies. But researchers are increasingly looking beyond the diagnosis and asking bigger questions about the biology that drives neurodegeneration.
That broader perspective is the focus of the first episode in the Pearson podcast series, “The Progress Profile: Alzheimer’s Research in Focus.”
In this episode, Lon Schneider, M.D., director of the California Alzheimer’s Disease Center at the University of Southern California; and Stephen Salloway, M.D., founding director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, join moderator John Harrison, Ph.D., associate professor of VU University Medical Center, to discuss the remarkable progress in Alzheimer’s research, the challenges that remain, and how advances in biomarkers, measurement, and early detection are changing the way scientists think about brain health.
Throughout the conversation, one message became clear: Understanding disease biology is just as important as understanding symptoms. Advances in Alzheimer’s research are creating new ways to identify pathology earlier, measure change with more accuracy, and develop interventions increasingly tailored to individual patients.
Rather than focusing only on where a patient is today, the conversation looked at where research is headed and how deeper biological understanding could transform the field.
Why Alzheimer’s Research Matters Beyond Alzheimer’s
The podcast highlighted the significant progress in Alzheimer’s research to date.
“[I]t’s taken a long time to get to this point where we are … able to target a core pathology of Alzheimer’s disease and see a clinical benefit, so this is a big step forward,” Salloway said. “[W]e’re at the beginning of a new era for the diagnosis and treatment of Alzheimer’s.”
For decades, the goal was to target a core pathology and demonstrate that treatment could modify it. Now, researchers can substantially lower amyloid and confirm those changes through imaging and, increasingly, blood-based testing. It’s led to the ability to identify disease based on underlying pathology rather than relying solely on clinical judgment.
These developments, Salloway acknowledged, are “big advances” that have allowed researchers to measure biological changes over time, enabling more precise biomarkers, molecular profiling, and better informed trial design. Clinical trials are becoming more precise, enrolling participants based not only on symptoms but also on disease stage and biological characteristics.
Salloway predicted that trials will become increasingly targeted to specific disease stages, based on the molecular phenotype of each patient. Schneider reinforced that progress comes from continually improving understanding of disease biology while simultaneously testing new therapeutic approaches.
Shared Lessons of Early Detection
One of the strongest themes throughout the episode is the importance — and difficulty — of detecting disease earlier.
Current evidence suggests that patients with milder disease and earlier biomarker profiles benefit most from amyloid-lowering treatments. That reality places increasing importance on identifying people before significant clinical decline occurs, but measuring those early changes presents new challenges.
Existing cognitive assessments focus heavily on episodic memory and might not be sophisticated enough to capture subtle changes in attention, working memory, and problem-solving. Schneider argued that current measures of instrumental activities of daily living are “really poor and not precise” and suggested moving toward passive assessments collected during everyday activity through smartphones and sensors rather than relying primarily on clinic-based evaluations or study-partner reports.
Salloway pointed to remote learning assessments completed on smartphones and tablets as promising approaches for detecting the earliest clinical signs. He also mentioned an enormous opportunity in measuring what people actually do at home rather than relying solely on structured, clinic-based tasks.
Medication management, financial transactions, speech patterns, and everyday digital interactions could further provide valuable information about subtle cognitive changes.
In preclinical populations, detecting change becomes even more difficult. When overall performance may still appear normal, researchers will need more sensitive measures and scalable approaches to identify meaningful differences over time.
What This Means for the Future of Brain Health
The conversation painted a picture of a future built around better biology, better measurement, and more precise care. Rather than applying the same approach to every patient, researchers are increasingly using molecular information to identify who is most likely to benefit from particular interventions.
“[W]e need better measures, [perhaps more] implicit and better sampling of function as a result of an intervention,” Schneider said.
An approach described as “molecular phenotyping” explains how patients with different biomarker profiles respond differently to treatment. Specifically, those with lower tau burden appear to benefit more from amyloid-lowering therapies than patients with higher tau levels. At the same time, researchers are exploring combination approaches that build on multiple strategies.
Schneider noted that Alzheimer’s care already includes combinations of medications alongside psychosocial, physical, environmental, and behavioral interventions. Clinical trials are similarly evolving, with studies examining how multiple therapies can work together rather than in isolation.
While acknowledging the “extraordinary ingenuity” in the clinical and academic research space, Harrison added, “The challenge is going to be bridging into clinical trials where currently we’re sort of stuck with things that are 40 or 50 years old and [are] really starting to show their age.”
Technology also plays an increasingly important role, and the panel discussed opportunities to incorporate digital cognitive assessments, speech analysis, navigation data, and real-world functional measures into research. These approaches could provide more meaningful information than traditional assessments developed decades ago, which may not reflect modern daily life.
Underlying all these developments is a growing emphasis on understanding the biology that drives disease progression, while developing tools to identify change earlier and more accurately.
Expanding the Conversation
The first episode of “The Progress Profile: Alzheimer’s Research in Focus” examined the evolving Alzheimer’s treatment landscape and the progress being made through clinical trials and illustrated how progress depends not only on new therapies but also on better ways to understand, measure, and monitor brain health.
To hear the full podcast and explore the ideas that are reshaping Alzheimer’s research, listen to episode 1 of “The Progress Profile: Alzheimer’s Research in Focus.”